Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Receivables (2021 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Change in Receivables for 5 consecutive years, with $1.0 million as the latest value for Q1 2025.

  • On a quarterly basis, Change in Receivables rose 280.18% to $1.0 million in Q1 2025 year-over-year; TTM through Sep 2025 was $363000.0, a 55.89% decrease, with the full-year FY2024 number at $415000.0, down 88.55% from a year prior.
  • Change in Receivables was $1.0 million for Q1 2025 at Whitehawk Therapeutics, up from -$637000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.7 million in Q1 2023 to a low of -$14.0 million in Q1 2021.
  • A 5-year average of -$483066.7 and a median of -$120000.0 in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: crashed 437.5% in 2022, then skyrocketed 930.81% in 2023.
  • Whitehawk Therapeutics' Change in Receivables stood at -$120000.0 in 2021, then tumbled by 232.5% to -$399000.0 in 2022, then surged by 42.61% to -$229000.0 in 2023, then tumbled by 178.17% to -$637000.0 in 2024, then soared by 256.99% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Change in Receivables are $1.0 million (Q1 2025), -$637000.0 (Q4 2024), and $620000.0 (Q3 2024).